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Background. Vancomycin-resistant Enterococcus (VRE) are important hospital-acquired pathogens among hematopoietic cell transplant (HCT) recipients. We examined the incidence and outcomes of patients with VRE colonization and bacteremia (VREB) over a ten-year period at a center that routinely screens and uses barrier precautions for VRE.
Methods. Adults receiving their first allogeneic HCT at our center between September 2007 and August 2016 were eligible for inclusion. Patients who were positive either by standardized pre-HCT stool/rectal screening or at any point two years prior to HCT were considered VRE colonized. Patients with acquired VRE were those with positive VRE cultures only post-HCT. Colonization and 100-day post-HCT VREB incidence rates were compared over time using linear regression. Cox proportional hazards models were constructed to assess the relationship between 100-day mortality and: a) pre-HCT colonization, and b) the number of days with sequential VREB cultures. Pre-transplant Assessment of Mortality (PAM) scores were calculated to allow adjustment for underlying disease severity.
Results. Of 1,492 eligible HCT recipients, 203 (14%) were colonized with VRE pre-HCT; an additional 90 (6.0%) acquired VRE colonization post-HCT. Forty-two patients (2.8%) developed VREB, the majority among those colonized with VRE (32 [76%] vs. 10 [24%] non-colonized). The cumulative incidence of VREB for the cohort was 2.9 per 10,000 patient-days. Over the study period, there were no significant changes in VRE colonization or VREB (P > 0.1). Those with multiple days with positive VRE blood cultures had significantly higher mortality than those with one positive culture (HR 3.9; 95% CI: 1.1, 14.0). Patients with pre-HCT colonization had an increased risk of death compared with non-colonized patients in an unadjusted model (HR 2.1: 95% CI: 1.4, 3.2) and after adjustment by PAM score (HR = 2.2; 95% CI: 1.5, 3.3). Patients with VRE (n = 299) accounted for 25,138 post-HCT isolation-days within the study period.
Conclusion. Despite nearly 15% of patients with pre-HCT colonization in our cohort, VREB was an infrequent post-HCT complication. Patients who developed prolonged VREB and those colonized with VRE pre-HCT had higher post-HCT mortality.
Disclosures Background. Neutropenic patients, specifically those with hematologic malignancies, are predisposed to higher rates of bloodstream infections compared with the general population. Neutropenia is also a risk factor for urinary tract related bloodstream infections. We hypothesized that neutropenic patients with asymptomatic bacteriuria have a higher rate of bacteremia compared with the general population.
Objectives. To evaluate the incidence of bacteremia in neutropenic patients with bacteriuria and to evaluate prior antibiotic use and presence of urinary symptoms in neutropenic patients with bacteremia from a urinary source.
Methods. This study took place in a large midwest tertiary hospital. A retrospective cohort study of all adult patients with AML, admitted February 2010 through November 2013, with subsequent neutropenia (ANC < 500) and positive urine cultures. The primary outcome was the rate of bacteremia with the same organism in neutropenic patients with bacteriuria. Information on microorganism, antibiotic use prior to culture, the presence of symptoms, and the urinalyses in this population were obtained through electronic records using the honest broker. This study was approved by the Institutional Review Board.
Results. In the initial cohort of 1,807 patients with AML, 139 patients had positive urine cultures. Of the 139 patients, 102 were neutropenic; 10/102 (9.8%) of neutropenic patients with bacteriuria developed bacteremia. Enterococcus faeciumwas the most common pathogen isolated (5/10). Seven of 10 bacteremic patients had no documented urinary symptoms. Seven of 10 of the bacteremic patients either did not receive antibiotics prior to obtaining urine and blood cultures or received antibiotics to which the pathogen was not susceptible. Seven of 10 of the urinalyses obtained tested negative for leukocyte esterase.
Conclusion. Approximately 10% of patients who were neutropenic with bacteriuria developed bacteremia. The majority of patients who became bacteremic did not have urinary symptoms or an abnormal urinalysis. This pilot study suggests that neutropenic patients with asymptomatic bacteriuria should be treated with antimicrobials, however, larger studies are necessary to confirm these findings.
Disclosures. All authors: No reported disclosures. Methods. This Single-center retrospective cohort included all AML patients receiving induction chemotherapy at West Penn Hospital from September 1, 2013 to April 30, 2017 who received antifungal prophylaxis with either posaconazole delayed release (DR) or voriconazole. The primary composite outcome was incidence of proven, probable, or possible IFI or initiation of an alternative antifungal for treatment of suspected or proven IFI. Secondary outcomes include the duration of inpatient length of stay (LOS), all-cause 100-day mortality, duration of neutropenia, and incidence of re-induction.
Comparison of Posaconazole and Voriconazole Prophylaxis Following
Results. The median duration of posaconazole and voriconazole was 18 and 20 days, respectively. There was no significant difference in the primary composite outcome between patients who received posaconazole or voriconazole (17% vs. 13%; P = 0.73). Baseline demographics and outcomes can be seen in Table 1. 
